Robust Industry Experience With over 60 years as API manufacturers and more than 40 years as a small molecule CDMO, AGC Pharma Chemicals demonstrates extensive industry expertise and a proven track record, making it a reliable partner for pharmaceutical companies seeking high-quality contract manufacturing solutions.

Recent Facility Expansion The company recently inaugurated a new advanced manufacturing plant in Barcelona with an investment of over 100 million euros, indicating a strategic capacity increase and potential for new manufacturing contracts for innovative pharmaceutical products.

Investment Commitment A significant €100 million investment into its Barcelona facility highlights AGC Pharma Chemicals' focus on expanding production capabilities and staying competitive, which can translate into increased supply and partnership opportunities for clients seeking reliable API production sources.

Strategic Industry Engagement Active participation in globally relevant events such as BioSpain 2025, Organic Process R&D Conference, BOS Basel 2025, and CPHI North America 2025 positions AGC Pharma Chemicals as a proactive player in the industry, offering opportunities to connect with potential partners and clients looking for innovative collaboration.

Market Position and Financials With revenues between 10-50 million dollars and a workforce of 201-500 employees, AGC Pharma Chemicals presents a growing but agile organization that can accommodate a diverse range of client needs, making it a compelling choice for pharmaceutical companies seeking dependable manufacturing partnerships.